

2022 Extraordinary General Meeting

Board of Director Candidates

Bill Fairey (Proposed Board Member)

Bill Fairey currently serves as Executive Chairman of Respira Therapeutics, Inc., a clinical-stage company developing inhaled therapeutics for cardiopulmonary diseases, a position he has held since January 2022. Since August 2021, Mr. Fairey has also served as a director of both Mirum Pharmaceuticals, a publicly-traded biotechnology company developing therapies for rare liver diseases, and Lung Therapeutics, Inc., a clinical-stage biopharmaceutical company.

Prior to Respira, Mr. Fairey was Executive Vice President and Chief Commercial Officer of MyoKardia, Inc., a publicly-traded clinical-stage biopharmaceutical company, from January 2019 until November 2020 when the company was acquired by Bristol-Myers Squibb. From January 2018 until January 2019, Mr. Fairey served as Executive Vice President and Chief Operating Officer of ChemoCentryx, Inc., a publicly-traded biopharmaceutical company developing therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases.

Before ChemoCentryx, between 2001 and 2017, Mr. Fairey served in various positions of increasing responsibility at Actelion Pharmaceuticals, including as President of Actelion's U.S. division, as well as Vice President, Asia Pacific Region, Managing Director and Vice President, Australia Asia Pacific Region, President of Actelion Canada, and Vice President, Sales and Managed Markets. Mr. Fairey began his pharmaceutical career as Business Director, Healthcare Management for the Parke-Davis Division of Warner-Lambert between 1988 and 2000.

Mr. Fairey received a B.S. in Biology from the University of Oregon and an M.B.A. from Saint Mary's College of California.

Siham Imani (Proposed Board Member)

Siham Imani currently serves as Executive Vice President Corporate Strategy of Servier, a global pharmaceutical group headquartered in France, a position she has held since April 2019. Prior to her current role, Ms. Imani was Servier's Director of Corporate Strategy from April 2017 until April 2019.

Before joining Servier, Ms. Imani held various positions of increasing responsibility at Ipsen, a French pharmaceutical company specializing in oncology, neuroscience and rare diseases, including Vice President European Business Unit Pediatric Endocrinology, Vice President Commercial Transformation & Support, Vice President Corporate Strategic Planning and Executive Committee Secretary, and Corporate Strategic Planning Director, from 2011 until April 2017. Ms. Imani also served as Projects Director of Pierre Fabre Medicament, a French pharmaceutical company, from 2010 to 2011, and as Marketing and Clinical Manager and European Marketing Manager of Biosense Webster, part of the Johnson & Johnson Family of Companies, from 2005 to 2010.

Ms. Imani received Master's degrees in Economics and Chemistry from École Polytechnique in Palaiseau, France and an M.B.A. from Stanford University.